Baidu
map

DDW 2016:EMR后粘膜缺损切缘热消融可显著减少腺瘤复发

2016-06-14 佚名 中国医学论坛报

本届美国消化疾病周上,一项即将公布的研究表明,内镜下粘膜切除术(EMR)后粘膜缺损切缘行热消融可显著降低首次结肠镜监测(SC1)时腺瘤复发率,常规应用此种简单安全的技术有可能增强EMR有效性并减少监测需求。  此项前瞻性多中心研究对EMR缺损切缘行辅助热消融能否降低腺瘤复发率进行了评估。主要终点为SC1时内镜和组织学复发。将标准注射和切除EMR技术应用于所有病变。排除标准包括既往尝试治疗病变、圈套

本届美国消化疾病周上,一项即将公布的研究表明,内镜下粘膜切除术(EMR)后粘膜缺损切缘行热消融可显著降低首次结肠镜监测(SC1)时腺瘤复发率,常规应用此种简单安全的技术有可能增强EMR有效性并减少监测需求。
  

此项前瞻性多中心研究对EMR缺损切缘行辅助热消融能否降低腺瘤复发率进行了评估。主要终点为SC1时内镜和组织学复发。将标准注射和切除EMR技术应用于所有病变。排除标准包括既往尝试治疗病变、圈套切除不完全和回盲瓣受累。EMR成功完整切除巨大无蒂和侧向发育结肠病变(LSL)并详细检查缺损以确保无残留腺瘤之后,以1:1比例将粘膜缺损随机给予缺损边缘热消融或不行附加治疗。在5至6个月时实施SC1,并实施标准化影像记录和瘢痕活检。
  
结果显示,共有768个≥20 mm病变接受EMR治疗,其中359个接受随机化,热消融和对照组分别为178和181个。两组的患者、操作和病变特征均相似。267例(74.3%)患者完成了SC1。SC1时,热消融组的内镜和组织学复发率均显著低于对照组(5.8%对20.2%,P<0.001,相对危险度[RR] 0.29;5.8%对20.6%,P=0.002,RR 0.28)。与组织学结果比较时,EMR后瘢痕内镜评估准确确定复发的敏感性、特异性和阴性预测值分别为100%、98%和100%。热消融和对照组在延迟出血和延迟穿孔发生率方面均无显著差异。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1690952, encodeId=5eef169095207, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Dec 09 12:23:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634234, encodeId=ba7816342342b, content=<a href='/topic/show?id=5abf6e2114f' target=_blank style='color:#2F92EE;'>#热消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67211, encryptionId=5abf6e2114f, topicName=热消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04a722134767, createdName=花花1373, createdTime=Mon May 22 16:23:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738705, encodeId=258e1e3870527, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6733, encryptionId=ac106e33e1, topicName=EMR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944034484276, createdName=ms1292405679162969, createdTime=Mon Jan 02 01:23:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421633, encodeId=69ab142163362, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429620, encodeId=24af1429620f5, content=<a href='/topic/show?id=97c25e83dd' target=_blank style='color:#2F92EE;'>#DDW#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5783, encryptionId=97c25e83dd, topicName=DDW)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de284221867, createdName=aids214, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=)]
    2016-12-09 guoyibin
  2. [GetPortalCommentsPageByObjectIdResponse(id=1690952, encodeId=5eef169095207, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Dec 09 12:23:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634234, encodeId=ba7816342342b, content=<a href='/topic/show?id=5abf6e2114f' target=_blank style='color:#2F92EE;'>#热消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67211, encryptionId=5abf6e2114f, topicName=热消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04a722134767, createdName=花花1373, createdTime=Mon May 22 16:23:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738705, encodeId=258e1e3870527, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6733, encryptionId=ac106e33e1, topicName=EMR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944034484276, createdName=ms1292405679162969, createdTime=Mon Jan 02 01:23:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421633, encodeId=69ab142163362, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429620, encodeId=24af1429620f5, content=<a href='/topic/show?id=97c25e83dd' target=_blank style='color:#2F92EE;'>#DDW#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5783, encryptionId=97c25e83dd, topicName=DDW)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de284221867, createdName=aids214, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1690952, encodeId=5eef169095207, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Dec 09 12:23:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634234, encodeId=ba7816342342b, content=<a href='/topic/show?id=5abf6e2114f' target=_blank style='color:#2F92EE;'>#热消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67211, encryptionId=5abf6e2114f, topicName=热消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04a722134767, createdName=花花1373, createdTime=Mon May 22 16:23:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738705, encodeId=258e1e3870527, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6733, encryptionId=ac106e33e1, topicName=EMR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944034484276, createdName=ms1292405679162969, createdTime=Mon Jan 02 01:23:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421633, encodeId=69ab142163362, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429620, encodeId=24af1429620f5, content=<a href='/topic/show?id=97c25e83dd' target=_blank style='color:#2F92EE;'>#DDW#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5783, encryptionId=97c25e83dd, topicName=DDW)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de284221867, createdName=aids214, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1690952, encodeId=5eef169095207, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Dec 09 12:23:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634234, encodeId=ba7816342342b, content=<a href='/topic/show?id=5abf6e2114f' target=_blank style='color:#2F92EE;'>#热消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67211, encryptionId=5abf6e2114f, topicName=热消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04a722134767, createdName=花花1373, createdTime=Mon May 22 16:23:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738705, encodeId=258e1e3870527, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6733, encryptionId=ac106e33e1, topicName=EMR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944034484276, createdName=ms1292405679162969, createdTime=Mon Jan 02 01:23:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421633, encodeId=69ab142163362, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429620, encodeId=24af1429620f5, content=<a href='/topic/show?id=97c25e83dd' target=_blank style='color:#2F92EE;'>#DDW#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5783, encryptionId=97c25e83dd, topicName=DDW)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de284221867, createdName=aids214, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1690952, encodeId=5eef169095207, content=<a href='/topic/show?id=7adce62603e' target=_blank style='color:#2F92EE;'>#粘膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76260, encryptionId=7adce62603e, topicName=粘膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=090129165428, createdName=guoyibin, createdTime=Fri Dec 09 12:23:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634234, encodeId=ba7816342342b, content=<a href='/topic/show?id=5abf6e2114f' target=_blank style='color:#2F92EE;'>#热消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67211, encryptionId=5abf6e2114f, topicName=热消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=04a722134767, createdName=花花1373, createdTime=Mon May 22 16:23:00 CST 2017, time=2017-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738705, encodeId=258e1e3870527, content=<a href='/topic/show?id=ac106e33e1' target=_blank style='color:#2F92EE;'>#EMR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6733, encryptionId=ac106e33e1, topicName=EMR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=944034484276, createdName=ms1292405679162969, createdTime=Mon Jan 02 01:23:00 CST 2017, time=2017-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421633, encodeId=69ab142163362, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429620, encodeId=24af1429620f5, content=<a href='/topic/show?id=97c25e83dd' target=_blank style='color:#2F92EE;'>#DDW#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5783, encryptionId=97c25e83dd, topicName=DDW)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de284221867, createdName=aids214, createdTime=Thu Jun 16 12:23:00 CST 2016, time=2016-06-16, status=1, ipAttribution=)]
    2016-06-16 aids214

相关资讯

医学消化系统的口诀

咽歌诀 咽部分三鼻口喉,前壁开口气食流; 上通鼓室下通喉,吞咽闭气不用愁。 食管与胃歌诀 食管三段颈胸腹,三个狭窄要记住; 胃居剑下左上腹,二门二弯又三部; 贲门幽门大小弯,胃底胃体幽门部; 小弯胃窦易溃疡,及时诊断莫延误。 小肠歌诀 小肠弯又长,盘曲在腹腔; 上段十二指,中下空回肠; 全长约五米,空回二三量。 十二指肠歌诀 四部上降下和升,右包胰头“C”字型; 降部后

Gastroenterology:他汀类药物对代偿性肝硬化患者的影响

他汀药物治疗可降低肝硬化患者的门静脉压以及增加静脉曲张伴返伴流时间。他汀药物可能具有肝毒素性作用,所以确定长期使用他汀对肝硬化患者是否有害是很重要的事。本研究旨在评估他汀类药物对代偿性肝硬化患者的影响。 研究人员根据退伍军人临床病例注册进行了一项回顾性队列研究,研究对象来自于全国范围内的丙型肝炎病毒(HCV)患者。研究人员纳入了来自1996年1月到2009年12月代偿性肝硬化患者。依据所开的处方

Appetite:老人胃口好 死亡远离他

近日,来自澳洲莫纳斯大学的研究人员通过研究表示,食欲(胃口)或可有效改善老年人的身体健康状况,帮助降低其死亡的风险,相关研究成果发表于国际杂志Appetite上。 研究者Mark Wahlqvist教授说道,食欲一般被认为是指示机体健康的重要指示器,而老年人往往对食物的冲动会发生明显降低,很多老年个体都会产生厌食症,而咀嚼困难及药物的副作用也会明显抑制老年人的食欲,家庭的事件及其它环境因子也会影

具有消化系统表现的白塞病的临床特点

白塞病(Behcet’s disease,BD)是一种慢性全身性血管炎症性疾病,主要表现为复发性口腔溃疡、生殖器溃疡、眼炎及皮肤损害,也可累及血管、神经系统、消化道、关节、肺、肾、附睾等器官。本病在东亚、中东和地中海地区发病率较高,好发年龄为16~40岁。白塞病的消化道损害又称肠白塞(intestial Behcet’s disease),发病率在4%~50%,临床上常需与炎症性肠病、肠结核等

胰腺,一个让人敬畏的器官

导读:今天说说人体一个独特的器官。 胰腺,一个独特的器官。象一条鱼躺在人体左上腹的最深面,前面是胃后面是错综复杂的血管和神经组织。不过,它的特殊不止这些,仔细读来才知,它是个让人敬畏的器官。   1、老人们常说的“胰子” 上年纪的人记得,小时洗手用的肥皂叫“胰子”。肥皂发明前,先人就知道动物的胰脏可去油污,用宰杀动物胰脏在手或衣服上搓刷,油渍即

Gastroenterology:IBD患者在急诊手术的术后死亡率更高

在紧急肠道切除术后,对于炎症性肠病的发生研究报道不同。本研究以人群为基础进行了一项系统回顾和荟萃分析来确定肠道切除术后IBD患者术后死亡率。研究人员在Medline、EMBASE,PubMed等数据库检索了从1990年到2015年的相关研究报告,并选定了来自15个国家相关IBD患者术后死亡率的18篇文章和3篇报告的摘要,其中包括67057例溃疡性结肠炎(UC)患者和75971例克罗恩病(CD)。这

Baidu
map
Baidu
map
Baidu
map